Table 3.
Five-year survival rates by histology group and WHO grade, NCDB 2004–2014.
| Grade I | Grade II | Grade III | Grade IV | NA | Total | |
|---|---|---|---|---|---|---|
| Neuronal and mixed neuronal-glial tumors | 94.9% (94.0%–95.8%) | 88.6% (85.8%–91.5%) | 44.2% (34.7%–53.7%) | 31.8% (16.3%–47.2%) | 88.8% (87.0%–90.6%) | 90.7% (89.9%–91.6%) |
| Primary melanocytic lesions | - | - | - | - | 31.2% (24.1%–38.4%) | 31.2% (24.1%–38.4%) |
| Mesenchymal tumors | 92.2% (83.3%–100%) | 86.2% (81.2%–91.3%) | 63.0% (55.4%–70.7%) | 51.4% (36.0%–66.9%) | 77.4% (75.1%–79.7%) | 76.8% (74.8%–78.8%) |
| Embryonal tumors | 93.1% (83.9%–100%) | 100% (100%–100%) | 20.0% (0.0%–55.1%) | 64.2% (62.8%–65.6%) | 76.1% (70.8%–81.4%) | 64.9% (63.5%–66.2%) |
| Germ cell tumors, cysts, and heterotopias | - | - | - | - | 89.0% (87.1%–90.8%) | 89.0% (87.1%–90.8%) |
| Hemangioma | - | - | - | - | 87.5% (86.6%–88.5%) | 87.5% (86.6%–88.5%) |
| Other neoplasms related to the meninges | - | - | - | - | 87.9% (86.8%–88.9%) | 87.9% (86.8%–88.9%) |
| Craniopharyngioma | 77.5% (74.6%–80.5%) | - | - | - | - | 77.5% (74.6%–80.5%) |
| Other neuroepithelial tumors | 100% (100%–100%) | 71.8% (54.5%–89.0%) | 53.0% (26.2%–79.8%) | 31.3% (3.9%–58.6%) | 70.5% (60.7%–80.4%) | 67.7% (60.0%–75.5%) |
| Glioma malignant, NOS | 69.5% (64.6%–74.3%) | 64.7% (60.1%–69.3%) | 17.9% (14.1%–21.7%) | 11.1% (8.5%–13.8%) | 44.6% (43.5%–45.8%) | 43.2% (42.1%–44.2%) |
| Unique astrocytoma variants | 90.3% (85.8%–94.7%) | 72.2% (67.1%–77.2%) | 23.5% (16.4%–30.6%) | 32.4% (18.8%–46.1%) | 58.2% (54.1%–62.3%) | 61.2% (58.5%–63.9%) |
| Oligoastrocytic tumors | 60.0% (46.5%–73.6%) | 78.3% (76.5%–80.1%) | 54.8% (52.5%–57.1%) | 28.4% (24.0%–32.9%) | 55.9% (51.5%–60.3%) | 63.1% (61.7%–64.5%) |
| Ependymal tumors | 89.7% (89.0%–90.4%) | 85.0% (78.8%–91.2%) | 62.2% (58.3%–66.0%) | 59.4% (48.5%–70.3%) | 82.8% (80.3%–85.3%) | 86.8% (86.1%–87.5%) |
| Choroid plexus tumors | 92.8% (89.7%–95.9%) | 76.2% (64.8%–87.7%) | 72.8% (60.3%–85.4%) | 67.5% (37.1%–97.9%) | 83.0% (79.7%–86.2%) | 85.1% (82.8%–87.4%) |
| Diffuse astrocytoma | 67.9% (63.5%–72.3%) | 60.8% (59.5%–62.1%) | 29.5% (27.8%–31.2%) | 9.1% (7.6%–10.5%) | 42.9% (41.1%–44.7%) | 44.3% (43.4%–45.1%) |
| Anaplastic astrocytoma | 39.5% (15.5%–63.5%) | 47.6% (37.8%–57.4%) | 29.7% (28.6%–30.7%) | 19.6% (17.4%–21.7%) | 29.8% (27.0%–32.5%) | 28.5% (27.6%–29.4%) |
| Pilocytic astrocytoma | 91.6% (90.8%–92.3%) | - | - | - | - | 91.6% (90.8%–92.3%) |
| Glioblastoma | - | - | - | 6.0% (5.8%–6.2%) | - | 6.0% (5.8%–6.2%) |
| Oligodendroglioma | 77.1% (70.4%–83.9%) | 85.7% (84.6%–86.8%) | 65.9% (61.5%–70.3%) | 28.8% (22.9%–34.7%) | 71.0% (68.0%–74.0%) | 79.8% (78.8%–80.8%) |
| Anaplastic oligodendroglioma | 66.7% (35.9%–97.5%) | 74.5% (64.5%–84.5%) | 62.7% (60.5%–64.9%) | 45.1% (40.3%–50.0%) | 59.4% (53.9%–64.9%) | 60.3% (58.4%–62.1%) |
| Meningiomas | 76.1% (75.9%–76.3%) | 78.8% (77.9%–79.8%) | 48.7% (45.6%–51.7%) | - | - | 76.1% (75.9%–76.3%) |
| Nerve sheath tumors | 93.0% (92.8%–93.3%) | - | - | - | 86.8% (85.1%–88.4%) | 92.8% (92.5%–93.1%) |
| Other tumors of cranial and spinal nerves | - | - | - | - | 93.8% (85.4%–100%) | 93.9% (85.8%–100%) |
| Neoplasm, unspecified | 88.6% (83.1%–94.1%) | 61.1% (44.9%–77.2%) | 29.6% (15.5%–43.8%) | 17.1% (7.0%–27.2%) | 44.6% (43.4%–45.7%) | 45.1% (44.0%–46.3%) |
| All other | 67.3% (40.6%–94.0%) | - | 50.0% (1.0%–99.0%) | 20.0% (0.0%–55.1%) | 61.5% (52.2%–70.8%) | 60.4% (51.9%–68.9%) |